STOCK TITAN

Cronos Group Inc. to Speak at the Canaccord Genuity 7th Annual Global Cannabis Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cronos Group Inc., an innovative global cannabinoid company, announced that Mike Gorenstein, Chairman, President and CEO, will speak at the Canaccord Genuity 7th Annual Global Cannabis Conference on May 18, 2023. A live webcast will be available on the Company's website.
Positive
  • None.
Negative
  • None.

TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the Canaccord Genuity 7th Annual Global Cannabis Conference on Thursday, May 18, 2023, at 11:00AM ET.

A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations.

About Cronos Group Inc.
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos’ intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and quarterly report on Form 10-Q for the quarter ended March 31, 2023, which have been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Group Contact
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com


FAQ

When is the Canaccord Genuity 7th Annual Global Cannabis Conference?

The conference will take place on May 18, 2023.

Who will be speaking at the conference?

Mike Gorenstein, Chairman, President and CEO of Cronos Group Inc., will be speaking at the conference.

Where can I watch the conference?

A live webcast of the conference will be available on the Investors section of Cronos Group Inc.'s website at https://ir.thecronosgroup.com/events-presentations.

Cronos Group Inc. Common Share

NASDAQ:CRON

CRON Rankings

CRON Latest News

CRON Stock Data

716.80M
200.23M
46.4%
15.62%
1.02%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
United States of America
STAYNER